Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rimeporide SCHEMBL29404681 | 1.00 | SLC9A1 (0.55) | SLC9A1 | |
| Rimeporide SCHEMBL6674301 | 0.98 | SLC9A1 (0.54) | SLC9A1 | |
| Rimeporide SCHEMBL1021018 | 0.98 | SLC9A1 (0.54) | SLC9A1 | |
| Rimeporide SCHEMBL16712397 | 0.98 | SLC9A1 (0.54) | SLC9A1 | |
| Rimeporide SCHEMBL1020612 | 0.97 | SLC9A1 (0.52) | SLC9A1 | |
| SCHEMBL20077671 | 0.84 | SLC9A1 (0.40) | SLC9A1 | |
| Eniporide SCHEMBL6619621 | 0.83 | SLC9A1 (0.63) | SLC9A1 | |
| SCHEMBL13813420 | 0.82 | LMNA (0.41) | SLC9A1 | |
| Eniporide SCHEMBL6623628 | 0.82 | SLC9A1 (0.62) | SLC9A1 | |
| SCHEMBL7648226 | 0.79 | SLC9A1 (0.40) | SLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2671576-B1 | Pharmaceutical composition for treating diseases associated with insulin resistance and ß-cell dysfunction | MERCK PATENT GMBH (DE) | 2020-04-08 | — | — | EP | claimed |
| US-10292949-B2 | Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and β-cell dysfunction | MECK PATENT GMBH (DE) | 2019-05-21 | — | — | US | claimed |
| US-20170189354-A1 | PHARMACEUTICAL COMPOSITION COMPRISING RIMEPORIDE FOR TREATING DISEASES ASSOCIATED WITH INSULIN RESISTANCE AND BETA-CELL DYSFUNCTION | MERCK PATENT GMBH (DE) | 2017-07-06 | — | — | US | claimed |
| EP-2271327-B1 | Pharmaceutical composition comprising rimeporide for treating diseases associated with beta-cell dysfunction | MERCK PATENT GMBH (DE) | 2015-05-20 | — | — | EP | claimed |
| EP-2671576-A1 | Pharmaceutical composition for treating diseases associated with insulin resistance and ß-cell dysfunction | Merck Patent GmbH (DE) | 2013-12-11 | — | — | EP | claimed |
| US-8530516-B2 | Promoting cycling of ApoE4 isoform | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-09-10 | — | — | US | claimed |
| WO-2011071920-A2 | PROMOTING CYCLING OF APOE4 ISOFORM | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-06-16 | — | — | WO | claimed |
| US-20110136832-A1 | Promoting Cycling of ApoE4 Isoform | University of Texas , Board of Regents | 2011-06-09 | — | — | US | claimed |
| US-20110060051-A1 | PHARMACEUTICAL COMPOSITION COMPRISING RIMEPORIDE FOR TREATING DISEASES ASSOCIATED WITH INSULIN RESISTANCE AND BETA-CELL DYSFUNCTION | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-03-10 | — | — | US | claimed |
| EP-2271327-A1 | PHARMACEUTICAL COMPOSITION COMPRISING RIMEPORIDE FOR TREATING DISEASES ASSOCIATED WITH INSULIN RESISTANCE AND BETA-CELL DYSFUNCTION | Merck Patent GmbH (DE) | 2011-01-12 | — | — | EP | claimed |
| WO-2009135583-A1 | PHARMACEUTICAL COMPOSITION COMPRISING RIMEPORIDE FOR TREATING DISEASES ASSOCIATED WITH INSULIN RESISTANCE AND BETA-CELL DYSFUNCTION | MERCK PATENT GMBH (DE) | 2009-11-12 | — | — | WO | claimed |
| EP-1146863-B1 | LYOPHILISATES WITH IMPROVED RECONSTITUTIBILITY | MERCK PATENT GMBH (DE) | 2004-05-12 | — | — | EP | claimed |
| US-6673968-B1 | REACTING 4-CHLORO-2-METHYL-5-(METHYLSULFONYL)BENZOIC ACID WITH SODIUM METHANESULFINATE, THEN WITH GUANIDINE, SALT FORMATION; ANTIARRHYTHMIC; NHE-1 SELECTIVE NA+/H+ ANTIPORTER INHIBITOR | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2004-01-06 | — | — | US | claimed |
| EP-1224166-B1 | METHOD OF PRODUCING N-(4,5-BIS-METHANESULFONYL-2-METHYL-BENZOYL)-GUANIDINE, THE HYDROCHLORIDE THEREOF | MERCK PATENT GMBH (DE) | 2003-09-17 | — | — | EP | claimed |
| EP-1224166-A1 | METHOD OF PRODUCING N-(4,5-BIS-METHANESULFONYL-2-METHYL-BENZOYL)-GUANIDINE, THE HYDROCHLORIDE THEREOF | MERCK PATENT GmbH (DE) | 2002-07-24 | — | — | EP | claimed |
| WO-2001030750-A1 | METHOD OF PRODUCING N-(4,5-BIS-METHANESULFONYL-2-METHYL-BENZOYL)-GUANIDINE, THE HYDROCHLORIDE THEREOF | MERCK PATENT GMBH (DE) | 2001-05-03 | — | — | WO | claimed |
| US-12533309-B2 | Minoxidil adjuvant therapies | CARING BRANDS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250360128-A1 | MINOXIDIL ADJUVANT THERAPIES | JUPITER WELLNESS INC (US) | 2025-11-27 | — | — | US | disclosed |
| WO-2001030750-A1 | METHOD OF PRODUCING N-(4,5-BIS-METHANESULFONYL-2-METHYL-BENZOYL)-GUANIDINE, THE HYDROCHLORIDE THEREOF | MERCK PATENT GMBH (DE) | 2001-05-03 | — | — | WO | disclosed |
| WO-2001030750-A1 | METHOD OF PRODUCING N-(4,5-BIS-METHANESULFONYL-2-METHYL-BENZOYL)-GUANIDINE, THE HYDROCHLORIDE THEREOF | MERCK PATENT GMBH (DE) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533309-B2 | Minoxidil adjuvant therapies | RXRG, RXRA, RXRB | SLC9A1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.